Published in Ann Neurol on September 01, 1995
The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol (2005) 2.39
Fatigue: an important feature of late-onset Pompe disease. J Neurol (2007) 1.31
Molecular diagnosis of German patients with late-onset glycogen storage disease type II. J Inherit Metab Dis (2008) 0.89
Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. J Inherit Metab Dis (2014) 0.88
The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients. J Inherit Metab Dis (2011) 0.82
Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease. Cell Mol Life Sci (2010) 0.82
Phenotypical variation within 22 families with Pompe disease. Orphanet J Rare Dis (2013) 0.81
Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature. J Neurol (2013) 0.80
Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study. Eur J Pediatr (2014) 0.79
Isolated elevated serum transaminases leading to the diagnosis of asymptomatic Pompe disease. Eur J Pediatr (2006) 0.75
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum Mol Genet (2001) 2.95
[The symptomatic treatment of amyotrophic lateral sclerosis]. Ned Tijdschr Geneeskd (2004) 2.61
Primary structure and processing of lysosomal alpha-glucosidase; homology with the intestinal sucrase-isomaltase complex. EMBO J (1988) 2.44
Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man. Proc Natl Acad Sci U S A (1982) 2.39
Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature (1993) 2.36
Histochemical aspects of five limb muscles in old age. An autopsy study. J Neurol Sci (1971) 2.03
[Peer review in requests for subsidy]. Ned Tijdschr Geneeskd (1997) 2.02
Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med (1990) 1.99
Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. Am J Hum Genet (1996) 1.89
Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet (2000) 1.84
Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet (1995) 1.81
Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet (1999) 1.76
Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. J Neurol Neurosurg Psychiatry (1993) 1.67
Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscul Disord (2010) 1.62
Introduction of a viral thymidine kinase gene and the human beta-globin gene into developmentally multipotential mouse teratocarcinoma cells. Proc Natl Acad Sci U S A (1980) 1.58
Data on the distribution of fibre types in five human limb muscles. An autopsy study. J Neurol Sci (1971) 1.51
Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol (2001) 1.47
The extensor digitorum brevis: histological and histochemical aspects. J Neurol Neurosurg Psychiatry (1972) 1.47
Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts. J Clin Invest (1987) 1.45
Defects in synthesis, phosphorylation, and maturation of acid alpha-glucosidase in glycogenosis type II. J Biol Chem (1985) 1.43
Botulinum toxin-induced myopathy in the rat. Brain (1995) 1.43
[Amyotrophic lateral sclerosis: mechanical ventilation--or not right?]. Ned Tijdschr Geneeskd (2004) 1.41
Point mutations throughout the GLI3 gene cause Greig cephalopolysyndactyly syndrome. Hum Mol Genet (1999) 1.40
The inferior oblique as muscle of choice for biopsies of extraocular muscles. Br J Ophthalmol (1979) 1.35
A new exon created by intronic insertion of a rearranged LINE-1 element as the cause of chronic granulomatous disease. Eur J Hum Genet (2000) 1.35
Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem (1993) 1.32
Tay-Sachs and Sandhoff's disease: intergenic complementation after somatic cell hybridization. Exp Cell Res (1974) 1.32
Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry (1995) 1.31
TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex. Hum Mol Genet (2001) 1.31
Chronic idiopathic axonal polyneuropathy: a five year follow up. J Neurol Neurosurg Psychiatry (1994) 1.29
Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry (1993) 1.28
Development of innervation of skeletal muscle fibers in man: relation to acetylcholine receptors. Anat Rec (1993) 1.28
Characterization of the human lysosomal alpha-glucosidase gene. Biochem J (1990) 1.26
Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis (2001) 1.25
Expression and routeing of human lysosomal alpha-glucosidase in transiently transfected mammalian cells. Biochem J (1990) 1.24
Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies. Hum Genet (1983) 1.22
Determination of Gaucher's disease phenotypes with monoclonal antibody. Clin Chim Acta (1983) 1.22
Biochemical, immunological, and cell genetic studies in glycogenosis type II. Am J Hum Genet (1978) 1.20
Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Biochem Biophys Res Commun (1994) 1.17
Deletion of the serine 34 codon from the major peripheral myelin protein P0 gene in Charcot-Marie-Tooth disease type 1B. Nat Genet (1993) 1.17
Deletion at chromosome 16p13.3 as a cause of Rubinstein-Taybi syndrome: clinical aspects. Am J Hum Genet (1993) 1.16
Human lysosomal alpha-glucosidase. Characterization of the catalytic site. J Biol Chem (1991) 1.15
Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum Mol Genet (1998) 1.14
The effect of a single base pair deletion (delta T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease type II. Hum Mol Genet (1994) 1.14
Biosynthesis and intracellular transport of alpha-glucosidase and cathepsin D in normal and mutant human fibroblasts. Eur J Biochem (1985) 1.13
Rubinstein-Taybi syndrome caused by submicroscopic deletions within 16p13.3. Am J Hum Genet (1993) 1.12
Genetic heterogeneity in GM1-gangliosidosis. Nature (1975) 1.11
Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet (1999) 1.10
Glycogenosis type II (acid maltase deficiency). Muscle Nerve Suppl (1995) 1.09
Monoclonal antibodies against human beta-glucocerebrosidase. Eur J Biochem (1983) 1.08
Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. J Neurol Sci (1989) 1.08
Isolation and characterization of a precursor form of lysosomal alpha-glucosidase from human urine. Eur J Biochem (1984) 1.05
Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites. Biochem J (1993) 1.05
Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. Blood (1990) 1.05
Histochemical fibre types in human extraocular muscles, an investigation of inferior oblique muscle. Acta Neuropathol (1979) 1.04
Morphological changes in the human end plate with age. J Neurol Sci (1990) 1.03
Carnitine palmitoyltransferase II deficiency with normal carnitine palmitoyltransferase I in skeletal muscle and leucocytes. J Neurol Sci (1979) 1.02
Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: new mutations and the paradox between genotype and phenotype. J Med Genet (1996) 1.01
Allosteric activation of acid alpha-glucosidase by the human papillomavirus E7 protein. J Biol Chem (2000) 1.00
Mucopolysaccharides in suspensions of Treponema pallidum extracted from infected rabbit testes. Genitourin Med (1985) 1.00
Recurrent and founder mutations in the Netherlands: the cardiac phenotype of DES founder mutations p.S13F and p.N342D. Neth Heart J (2012) 0.99
Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase. Eur J Biochem (1995) 0.99
Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. J Clin Invest (1991) 0.99
GM1-gangliosidosis. Defective recognition site on beta-galactosidase precursor. J Biol Chem (1986) 0.99
The status of HMSN type III. Neuromuscul Disord (1994) 0.99
Striking anticipation in spinocerebellar ataxia type 7: the infantile phenotype. J Neurol (2001) 0.98
Two divergent types of nerve pathology in patients with different P0 mutations in Charcot-Marie-Tooth disease. Neurology (1996) 0.98
Is episialin/MUC1 involved in breast cancer progression? Cancer Lett (1995) 0.98
The clinical spectrum of limb girdle muscular dystrophy. A survey in The Netherlands. Brain (1996) 0.98
De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer. J Med Genet (2001) 0.97
Immunoglobulin G subclasses of fluorescent anti-Treponema pallidum antibodies: evidence for sequential development of specific anti-T. pallidum immunoglobulin G responses in patients with early syphilis. J Clin Microbiol (1986) 0.97
Copy number changes of the microcephalin 1 gene (MCPH1) in patients with autism spectrum disorders. Clin Genet (2009) 0.97
alpha-N-acetylgalactosaminidase deficiency, a new lysosomal storage disorder. J Inherit Metab Dis (1988) 0.97
Physical mapping of the holoprosencephaly critical region in 21q22.3, exclusion of SIM2 as a candidate gene for holoprosencephaly, and mapping of SIM2 to a region of chromosome 21 important for Down syndrome. Am J Hum Genet (1995) 0.97
Discovery of the short gamma-ray burst GRB 050709. Nature (2005) 0.96
Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Hum Mol Genet (1998) 0.96
Cotransfer of syntenic human genes into mouse cells using isolated metaphase chromosomes or cellular DNA. Hum Genet (1985) 0.96
Autosomal recessive form of hereditary motor and sensory neuropathy type I. Neurology (1992) 0.96
Prospect for enzyme therapy in glycogenosis II variants: a study on cultured muscle cells. J Neurol (1988) 0.96
Early morphological features in dominantly inherited demyelinating motor and sensory neuropathy (HMSN type I). J Neurol Sci (1992) 0.95
The subcellular localization of soluble and membrane-bound lysosomal enzymes in I-cell fibroblasts: a comparative immunocytochemical study. Eur J Cell Biol (1985) 0.95